此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Improving Endovascular Treatment Through Process Refinements (ANGEL-IMPROVE)

2026年11月17日 更新者:Beijing Tiantan Hospital

Implementing Multiple Process Refinements for Optimal Value in Endo-vascular Treatment: A Cluster Randomized Clinical Trial

This study aims to evaluate the effectiveness of a structured, multi-component intervention package-the TIPS system-in improving the workflow and outcomes of endovascular treatment (EVT) for acute ischemic stroke caused by large vessel occlusion (LVO) in China. Despite EVT being a guideline-recommended therapy, delays in workflow processes such as door-to-puncture time (DTP) and puncture-to-reperfusion time (PRT) remain widespread, especially in developing countries. The TIPS intervention focuses on key structure-process-outcome (SPO) elements and includes training & discussion, indicator feedback, professional guidance, and a solutions toolkit, implemented through a PDSA (Plan-Do-Study-Act) cycle. This multicenter, cluster-randomized study will assess whether the TIPS intervention improves EVT process efficiency and patient functional outcomes (90-day mRS). The findings are expected to support quality improvement and promote equitable stroke care delivery across China.

研究概览

详细说明

This study aims to evaluate the effectiveness of a structured, multi-component quality improvement intervention (the TIPS system) in enhancing the workflow and patient outcomes of endovascular treatment (EVT) for acute ischemic stroke due to large vessel occlusion (LVO) in China. Although EVT is the guideline-recommended treatment, real-world data from both developed and developing countries demonstrate persistent delays in key workflow intervals, such as door-to-puncture time (DTP) and puncture-to-reperfusion time (PRT), which are associated with functional outcomes.

The TIPS system integrates four core components: Training & Discussion, Indicator Feedback, Professional Guidance, and a Solutions Toolkit. It follows the Plan-Do-Study-Act (PDSA) model for continuous quality improvement and is built on the structure-process-outcome (SPO) framework. The intervention involves structured training, real-time data monitoring using an electronic data capture (EDC) platform, a 24/7 expert consultation team, and smart workflow tools such as the iStroke system and GreenFast app to support process tracking and decision-making.

ANGEL-IMPROVE is a multicenter, prospective, open-label, cluster-randomized trial with blinded endpoint assessment. A total of 100 tertiary hospitals across China will be stratified and randomized to either the intervention or control group. The study will enroll approximately 1,400 adult patients (≥18 years) receiving EVT. Control group hospitals will continue standard care; intervention group hospitals will implement the TIPS program.

The primary outcome is door-to-puncture time (DTP), defined as the time from arrival at the emergency department to arterial puncture, with a target of less than 90 minutes. Secondary outcomes include puncture-to-reperfusion time (PRT, target <60 minutes), successful reperfusion defined as mTICI ≥2b, functional outcomes including the proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, full mRS distribution, NIHSS scores at 24 hours and 7 days or discharge, and EQ-5D scores at 90 days. Safety outcomes include serious intraoperative complications (such as vessel perforation, dissection, or embolism), symptomatic intracranial hemorrhage within 48 hours based on Heidelberg criteria, any intracranial hemorrhage within 48 hours, stroke-related mortality, all-cause mortality, and serious adverse events within 90 days according to ICH-GCP definitions.

Statistical analysis will follow the intention-to-treat principle using the Full Analysis Set (FAS); Per Protocol Set (PPS) will be used for sensitivity analysis, and Safety Analysis Set (SAS) for safety evaluation. Continuous variables will be summarized as mean ± SD or median (IQR), and categorical variables as counts and percentages; group comparisons will use standard parametric or nonparametric tests. The primary outcome will be analyzed using generalized linear mixed models (GLMM) accounting for hospital-level clustering, time effects, and patient-level covariates. Secondary outcomes will be analyzed using ordinal logistic regression or Wilcoxon test for ordered variables, linear mixed models for continuous variables, and GLMM for binary outcomes; time-to-event outcomes will use Kaplan-Meier and Cox models. Safety events will be descriptively summarized in the SAS, with group comparisons using chi-square or Fisher's exact tests. All tests will be two-sided with a significance level of P < 0.05.

This trial aims to develop a replicable, scalable model of EVT workflow optimization in low- and middle-income settings and promote more equitable access to high-quality stroke care in China.

研究类型

介入性

注册 (估计的)

2862

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Beijing、中国
        • 招聘中
        • Beijing Tiantan Hospital
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100010
        • 招聘中
        • Beijing Tiantan Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Eligibility Criteria Inclusion Criteria for Participating Centers

  • Tertiary hospitals (county-level hospitals preferred)
  • Equipped with an emergency department and a neurology ward that admits stroke patients
  • Capable of performing intravenous thrombolysis and endovascular treatment for acute ischemic stroke
  • Availability of a 24/7 in-hospital stroke emergency response team
  • Site principal investigator (PI) is committed to promoting the study, and the stroke team is willing to follow the study protocol, including randomization and interventions

Inclusion Criteria for Patients

  • Age ≥ 18 years
  • Undergoing endovascular treatment for acute ischemic stroke
  • Admitted through the emergency department
  • Written informed consent obtained from the patient or legally authorized representative for participation and follow-up

Exclusion Criteria for Participating Centers

  • Specialty hospitals (e.g., oncology, obstetrics/gynecology, pediatrics)
  • Fewer than 50 EVT cases per year for acute ischemic stroke
  • Inability to comply with the study protocol
  • Participation in other stroke-related quality improvement programs or clinical trials

Exclusion Criteria for Patients

  • Life expectancy less than 3 months or presence of severe comorbidities
  • Refusal to provide informed consent or inability to complete follow-up due to lack of consent or data sharing restrictions

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention Group

Participants in the intervention arm will receive the TIPS system, a structured quality improvement package designed to optimize EVT workflow. TIPS stands for Training & discussion, Indicator feedback, Professional guidance, and Solutions toolkit. The intervention includes team-based training, data-driven performance feedback, expert-led consultations, and workflow tools such as iStroke and GreenFast, implemented through iterative Plan-Do-Study-Act (PDSA) cycles. Real-time monitoring and data management are supported by an integrated electronic data capture (EDC) platform.

This intervention consists of a structured, multicomponent quality improvement program named TIPS, designed to optimize endovascular treatment (EVT) workflow in acute ischemic stroke. TIPS stands for Training & Discussion, Indicator Feedback, Professional Guidance, and Solutions Toolkit. The program includes standardized training sessions, real-time performance feedback via an electronic data capture (EDC) system, 24/7 expert consultation, and process management tools such as the iStroke platform and GreenFast pathway. The intervention is delivered at the hospital level and implemented using a Plan-Do-Study-Act (PDSA) cycle. It is distinct from other QI initiatives by its structured SPO-based design (Structure-Process-Outcome) and its integration of real-time data monitoring and expert-guided iterative feedback.

无干预:Control Group

Conventional Endovascular Treatment Process

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Door-to-Puncture Time (DTP)
大体时间:Periprocedural (from hospital arrival to arterial puncture)

DTP is defined as the time interval (in minutes) between a patient's arrival at the hospital emergency department (i.e., crossing the emergency entrance threshold) and the initiation of arterial access (puncture) in the angiography suite. It serves as a key indicator of workflow efficiency in endovascular treatment (EVT) for acute ischemic stroke. Shorter DTP is strongly associated with improved clinical outcomes. The threshold for achieving process quality is set at <90 minutes, as recommended by international guidelines. Time is measured from hospital records and procedural logs.

Periprocedural (from hospital arrival to arterial puncture)

次要结果测量

结果测量
措施说明
大体时间
Puncture-to-Reperfusion Time (PRT)
大体时间:Periprocedural

PRT is defined as the time interval between the start of arterial puncture and the achievement of successful reperfusion, as determined by digital subtraction angiography (DSA). It reflects intra-procedural efficiency during endovascular treatment (EVT). A PRT <60 minutes is considered a quality benchmark. Time is recorded from procedure start to documented final angiographic run.

Periprocedural
Successful Reperfusion (mTICI ≥2b)
大体时间:Periprocedural

Successful reperfusion is defined as achieving a modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b or higher on the final digital subtraction angiogram after EVT. This indicates restoration of adequate blood flow to the downstream territory. The mTICI scale ranges from 0 (no perfusion) to 3 (full perfusion), with 2b representing ≥50% filling of the affected territory.

Periprocedural
Functional Independence (mRS 0-2 at 90 days)
大体时间:90 days

Functional independence is defined as a score of 0-2 on the modified Rankin Scale (mRS) at 90 days post-treatment. The mRS measures the degree of disability or dependence in daily activities, ranging from 0 (no symptoms) to 6 (death). A score of 0-2 indicates independence in most daily functions.

90 days
NIHSS Score at 24 Hours and 7 Days (or Discharge)
大体时间:24 hours and 7 days (or Discharge)

The National Institutes of Health Stroke Scale (NIHSS) is a standardized measure used to assess neurological impairment following stroke. It ranges from 0 (no deficit) to 42 (severe stroke). NIHSS will be recorded at 24 hours and again at 7 days or hospital discharge, whichever occurs first, to monitor early neurological recovery.

24 hours and 7 days (or Discharge)
EQ-5D Quality of Life Score at 90 Days
大体时间:90 days

EQ-5D is a standardized measure of health-related quality of life consisting of five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has five levels of severity. Patients (or caregivers) will complete the EQ-5D questionnaire via structured follow-up interview at 90 days to assess overall health status.

90 days
All-cause mortality rate
大体时间:90 days

All-cause mortality rate at 90±14 days

90 days
Any type of intracranial hemorrhage
大体时间:36 hours

Any type of intracranial hemorrhage according to Heidelberg Classification.

36 hours
Symptomatic Intracranial Hemorrhage
大体时间:36 hours

Symptomatic Intracranial Hemorrhage according to Heidelberg Classification.

36 hours
Serious Intraoperative Complications
大体时间:Periprocedural

Defined as major adverse events occurring during the endovascular procedure, including but not limited to vessel perforation, dissection, acute occlusion, device malfunction (e.g., breakage), or distal embolization. These events require clinical intervention, may lead to procedure termination, and are considered to have potential impact on patient prognosis.

Periprocedural

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月15日

初级完成 (估计的)

2026年11月1日

研究完成 (估计的)

2027年2月1日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月17日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅